Revelation Biosciences, Inc. (REVB) News & Overview - Discounting Cash Flows
REVB
Revelation Biosciences, Inc.
REVB (NASDAQ)

REVB's Business Model

Revelation Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of immune system therapeutics and diagnostics. The company engages in developing therapeutic product candidates, including REVTx-99b that is in a Phase Ib clinical trial for the prevention or treatment of chronic nasal congestion and allergic rhinitis; and REVTx-200, a nonclinical stage product for intranasal therapy. It is also involved in developing REVTx-300, a non-clinical stage product that is being developed as a potential therapy for the treatment of chronic organ disease, including chronic kidney disease and non-alcoholic steatohepatitis; and REVDx-501, a rapid test kit, which is a point of care in vitro diagnostic test that has the potential to detect respiratory viral infections, such as SARS-CoV-2, Influenza A, Influenza B, parainfluenza, or respiratory syncytial virus. The company was founded in 2020 and is based in San Diego, California.
Sector & Industry Healthcare / Biotechnology
Website https://www.revbiosciences.com
CEO (Chief Executive Officer) James M. Rolke
Number of Employees
IPO date November 17, 2020

REVB Latest News

Contact
CountryUS
Address4660 La Jolla Village Drive
CitySan Diego
StateCA
Phone650-800-3717
Zip Code92122
Other Identifiers
CIK0001810560
ISINUS76135L5075
CUSIP76135L101
Open2.5
Previous Close2.5797
Volume355.8 Thou.
Average Volume378.4 Thou.
Day’s Range2.45 – 2.5397
52 Week Range2.106-168
MA (50)5.27572
MA (200)18.70423
Market Cap1.7 Mil.
Shares Out.676.6 Thou.
Earnings DateAug 07, 2025
Beta
Last Dividend
EPS
PE

Industry Competitors for REVB

Company
Market Cap
discounting cash flows home logo

Discounting Cash Flows

Are you finding our services helpful? Review us on trustpilot logo Trustpilot
Have a question? Contact us